NC410

Phase 2Small molecule

NNextCure, Inc.

NC410 is one of 31 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

MS Contin

1 3

Medrol

Pfizer

Preclinical

1 4

Byetta

AstraZeneca

Preclinical

1 5

Active Comparator

Moderna

Preclinical

1 6

NC410

NNextCure, Inc.

Phase 2

1 7

Secretin-Ferring

Ferring

Preclinical

1 8

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

2 9

Rybelsus

Pfizer

Preclinical

1 10

Gemcitabine/nab-Paclitaxel

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Recruiting

Pancreatic Cancer

NCT06941857

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06941857·20 enrolled

Metastatic Solid Tumors1 trial

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

Active, not recruiting·NNextCure, Inc.·Phase 1/2·NCT05572684·97 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Terminated·NNextCure, Inc.·Phase 1/2·NCT04408599·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NC410. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NC410 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NC410. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NextCure, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNextCure, Inc.

NC410

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Pancreatic Cancer1 trial

Metastatic Solid Tumors1 trial

Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News